Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Amirah Al Idrus
Rosana Kapeller, entrepreneur in residence, GV
Sandra Glucksmann—Cedilla Therapeutics
Amirah Al Idrus
Alexandra “Sandra” Glucksmann, CEO, Cedilla Therapeutics
Daphne Koller, CEO, Insitro
Novartis enlists Microsoft to modernize drugs' path to market
Beth Snyder Bulik
Thursday, October 3, 2019
Novartis’ new collab with Microsoft leverages AI to streamline drug discovery, but the joint effort goes beyond just finding new treatments.
BeiGene, Sumitomo-Roivant, Roche-JHL and more—FiercePharmaAsia
Friday, September 13, 2019
BeiGene rebuffs claims that it inflated drug sales records; Sumitomo Dainippon pays $3 billion upfront for five "vants"; Genentech settles with JHL Biotech.
Pfizer, Gilead-Yuhan and more—FiercePharmaAsia
Friday, January 11, 2019
Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.
FiercePharmaAsia—Biogen-Eisai, vaccine scandal, Tsinghua and more
Friday, July 27, 2018
Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.
FiercePharmaAsia—Sun Pharma, Eisai, Takeda and more
Friday, June 15, 2018
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.
FiercePharmaAsia—Ono, Eisai, Sanofi and more
Friday, December 15, 2017
BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.
FiercePharmaAsia—Zai Lab, Takeda, Fosun and Shanghai Pharma
Friday, August 18, 2017
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.